Korro Bio, Inc.
NASDAQ:KRROBiotechnology
+$1.76 today
- Market cap
- $170.75M
- Beta
- 2.10
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$9.79
Volume 0.16M
Average 0.15M
KRRO Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Korro Bio, Inc.NASDAQ: KRRO
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $12.95M fell 34.4% year over year, behind the -15.8% change in trailing-twelve-month research & development. Sequentially, it rose 17.9% from the prior quarter. Over 3 fiscal years it compounded at +15.8% a year.
Context
- Research & development amounted to 1025.9% of revenue in FY2025, down 1776.2 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -34.4% toward the trailing-twelve-month pace of -15.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 65.58M USD
- Year-over-year change
- +3.0%
- 4-year CAGR
- +2.5%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 65.58M | +3.0% |
| FY2024 | 2024-12-31 | 63.64M | +11.2% |
| FY2023 | 2023-12-31 | 57.25M | +35.7% |
| FY2022 | 2022-12-31 | 42.2M | -28.9% |
| FY2021 | 2021-12-31 | 59.32M | — |
Research & Development vs competitors
How KRRO compares with its peers on the latest reported figures
- KRRO's LTM Mar 2026 research & development of $58.79M is the 8th highest of the 11 companies compared; the peer median is $80.85M.
- Its year-over-year change of -15.8% is the lowest of 9, against a peer median of +19.1%.
- Research & development amounts to 1530.1% of revenue for KRRO, versus a peer median of 6710.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $172.31M | +17.5% | +18.0% | — | |
| LTM Mar 2026 | $152.7M | +75.7% | +85.3% | — | |
| LTM Mar 2026 | $124.71M | +42.2% | +15.6% | — | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $98.75M | +56.7% | +82.8% | — |
| LTM Mar 2026 | $94.92M | +19.3% | +28.8% | — | |
| LTM Mar 2026 | $66.77M | -12.8% | -2.0% | 185483.3% | |
| LTM Mar 2026 | $61.84M | — | +24.0% | 6710.8% | |
| LTM Mar 2026 | $58.79M | -15.8% | +15.8% | 1530.1% | |
| LTM Mar 2026 | $55.94M | +19.0% | +24.4% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $28.47M | — | +131.7% | — |
| LTM Mar 2026 | $18.45M | -6.9% | -13.3% | 8.6% | |
| Peer median (excluding KRRO) | $80.85M | +19.1% | +24.2% | 6710.8% | |
Competitors are the stored peer set for KRRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 14.07M | 0 | 0 | 2.27M | 6.39M |
| Cost of Revenue | 3.84M | 0 | 0 | 0 | 4.28M |
| Gross Profit | 10.23M | 0 | 0 | 2.27M | 2.11M |
| Gross Margin | 72.7% | — | — | 100.0% | 33.0% |
| Research & Development | 59.32M | 42.2M | 57.25M | 63.64M | 65.58M |
| Selling, General & Admin | 34.93M | 16.8M | 36.54M | 30.55M | 28.16M |
| Operating Expenses | 94.26M | 59M | 84.53M | 94.18M | 89.45M |
| Depreciation & Amortization | 3.84M | 2.51M | 3.63M | 3.57M | 4.28M |
| EBITDA | (80.07M) | (56.49M) | (80.9M) | (88.35M) | (83.06M) |
| EBITDA Margin | -569.1% | — | — | -3890.1% | -1299.5% |
| Operating Income | (84.03M) | (59M) | (84.53M) | (91.91M) | (87.34M) |
| Operating Margin | -597.3% | — | — | -4047.1% | -1366.4% |
| Interest Income | 397K | 947K | 0 | 0 | 0 |
| Interest Expense | 764K | 118K | 0 | 0 | 0 |
| Other Income / Expenses | (640K) | 976K | 3.39M | 8.47M | (29.28M) |
| Income Before Tax | (84.67M) | (58.02M) | (81.15M) | (83.44M) | (116.62M) |
| Pre-Tax Margin | -601.9% | — | — | -3674.2% | -1824.5% |
| Income Tax Expense | 15K | 10K | 27K | 141K | 637K |
| Net Income | (84.69M) | (58.03M) | (81.17M) | (83.58M) | (117.26M) |
| Net Margin | -602.0% | — | — | -3680.4% | -1834.5% |
| EPS (Basic) | (4.94) | (227.58) | (53.09) | (9.37) | (12.48) |
| EPS (Diluted) | (4.94) | (227.42) | (53.08) | (9.37) | (12.48) |
| Weighted Avg Shares | 4.45M | 255K | 1.53M | 8.92M | 9.4M |
| Weighted Avg Shares (Diluted) | 4.45M | 255.17K | 1.53M | 8.92M | 9.4M |
Korro Bio, Inc.
NASDAQ:KRRO
Intrinsic Alpha fair value
Locked
Current Price
$12.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.